PT  - JOURNAL ARTICLE
AU  - Kalra, Sanjay
AU  - Khan, Muhammad
AU  - Barlow, Laura
AU  - Beaulieu, Christian
AU  - Benatar, Michael
AU  - Briemberg, Hannah
AU  - Chenji, Sneha
AU  - Clua, Miriam Garrido
AU  - Cormier, Andre
AU  - Das, Sumit
AU  - Dionne, Annie
AU  - Dupré, Nicolas
AU  - Emery, Derek
AU  - Eurich, Dean
AU  - Frayne, Richard
AU  - Genge, Angela
AU  - Gibson, Summer
AU  - Graham, Simon
AU  - Hanstock, Christopher
AU  - Ishaque, Abdullah
AU  - Joseph, Jeffrey T.
AU  - Keith, Julia
AU  - Korngut, Lawrence
AU  - Krebs, Dennell
AU  - McCreary, Cheryl R.
AU  - Pattany, Fred
AU  - Seres, Peter
AU  - Shoesmith, Christen
AU  - Szekeres, Trevor
AU  - Tam, Fred
AU  - Welsh, Robert
AU  - Wilman, Alan
AU  - Yang, Yee Hong
AU  - Yunusova, Yana
AU  - Zinman, Lorne
AU  - ,
TI  - The Canadian ALS Neuroimaging Consortium (CALSNIC) - a multicentre platform for standardized imaging and clinical studies in ALS
AID  - 10.1101/2020.07.10.20142679
DP  - 2020 Jan 01
TA  - medRxiv
PG  - 2020.07.10.20142679
4099  - http://medrxiv.org/content/early/2020/07/15/2020.07.10.20142679.short
4100  - http://medrxiv.org/content/early/2020/07/15/2020.07.10.20142679.full
AB  - Background Amyotrophic lateral sclerosis (ALS) is a disabling and rapidly progressive neurodegenerative disorder. Increasing age is an important risk factor for developing ALS, thus the societal impact of this devastating disease will become more profound as the population ages. A significant hurdle to finding effective treatment has been an inability to accurately quantify cerebral degeneration associated with ALS in humans. Advanced magnetic resonance imaging (MRI) techniques hold promise in providing a set of biomarkers to assist in aiding diagnosis and in efficiently evaluating new drugs to treat ALS.Methods The Canadian ALS Neuroimaging Consortium (CALSNIC) was founded to develop and evaluate advanced MRI-based biomarkers that delineate biological heterogeneity, track disease progression, and predict survival in a large and heterogeneous sample of ALS patients.Findings CALSNIC has launched two studies to date (CALSINC-1, CALSNIC-2), acquiring multimodal neuroimaging, neurological, neuropsychological data, and neuropathological data from ALS patients and healthy controls in a prospective and longitudinal fashion from multiple centres in Canada and, more recently, the United States. Clinical and MRI protocols are harmonized across research centres and different MR vendors.Interpretation CALSNIC provides a multicentre platform for studying ALS biology and developing MRI-based biomarkers.Competing Interest StatementThe authors have declared no competing interest.Clinical TrialNCT02405182 and NCT03362658Clinical Protocols http://calsnic.org/ Funding StatementCALSNIC is funded by the Canadian Institutes of Health Research, the ALS Society of Canada, the Brain Canada Foundation, and the Shelly Mrkjonjic Research Fund.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study was approved by the health research ethics boards of each participating site, and all participants gave written informed consent.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesDetails of the protocols in this manuscript will be made available at http://calsnic.org/. http://calsnic.org/